 | Up a level |
Bousser, M G; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, H P; Rothwell, P M (2009). The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovascular diseases, 27(6), pp. 608-13. Basel: Karger 10.1159/000216835
Bousser, M G; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M G; Mattle, H P; Rothwell, P M (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular diseases, 27(5), pp. 509-18. Basel: Karger 10.1159/000212671
Andres, RH; Mattle, HP; Brainin, M; Chamorro, A; Diener, HD; Hacke, W; Leys, D; Norrving, B; Ward, N (2012). Further Aspects on Intravascular Stem Cell Therapy for Stroke. In: (pp. 95-1056). DGNC Mannheim
Andres, RH; Mattle, HP; Brainin, M; Chamorro, A; Diener, HD; Hacke, W; Leys, D; Norrving, B; Ward, N (2012). Further Aspects on Intravascular Stem Cell Therapy for Stroke. In: (pp. 2258-2265). Stroke
